Sumitomo Mitsui Trust Group Inc. Sells 15,074 Shares of GE HealthCare Technologies Inc. $GEHC

Key Points

• Sumitomo Mitsui Trust Group cut its position in GE HealthCare by 1.2%, selling 15,074 shares and retaining 1,207,630 shares (about 0.27% of the company) worth roughly $99.05 million.
• GE HealthCare beat quarterly expectations with $1.44 EPS vs. $1.40 consensus and revenue of $5.70B (+7.1% YoY), and set FY2026 guidance of EPS $4.95–5.15.
• Analyst sentiment is mixed—consensus is a Hold with an average target of $90.69—while the stock trades near $73.85, has a $33.69B market cap, P/E of 16.19, and a tiny 0.2% dividend yield.

Sumitomo Mitsui Trust Group Inc. cut its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 1.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,207,630 shares of the company's stock after selling 15,074 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 0.27% of GE HealthCare Technologies worth $99,050,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Howard Capital Management Inc. boosted its stake in GE HealthCare Technologies by 2.3% in the 4th quarter. Howard Capital Management Inc. now owns 13,033 shares of the company's stock valued at $1,069,000 after purchasing an additional 296 shares during the period. Carnegie Investment Counsel boosted its stake in GE HealthCare Technologies by 22.0% in the 4th quarter. Carnegie Investment Counsel now owns 25,498 shares of the company's stock valued at $2,091,000 after purchasing an additional 4,604 shares during the period. Apollon Wealth Management LLC boosted its stake in GE HealthCare Technologies by 8.7% in the 4th quarter. Apollon Wealth Management LLC now owns 13,502 shares of the company's stock valued at $1,107,000 after purchasing an additional 1,079 shares during the period. Fiduciary Alliance LLC bought a new stake in GE HealthCare Technologies in the 4th quarter valued at $217,000. Finally, V Square Quantitative Management LLC bought a new stake in GE HealthCare Technologies in the 4th quarter valued at $432,000. 82.06% of the stock is currently owned by institutional investors.

GE HealthCare Technologies Stock Performance

NASDAQ:GEHC opened at $73.85 on Tuesday. The stock has a fifty day moving average price of $76.01 and a 200-day moving average price of $77.97. The company has a market cap of $33.69 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 1.61 and a beta of 1.17. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.13 and a current ratio of 1.37. GE HealthCare Technologies Inc. has a fifty-two week low of $59.95 and a fifty-two week high of $89.77.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last released its earnings results on Wednesday, February 4th. The company reported $1.44 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.04. GE HealthCare Technologies had a return on equity of 21.35% and a net margin of 10.11%.The firm had revenue of $5.70 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same period in the prior year, the company posted $1.45 EPS. The company's revenue was up 7.1% compared to the same quarter last year. GE HealthCare Technologies has set its FY 2026 guidance at 4.950-5.150 EPS. As a group, equities analysts anticipate that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

GE HealthCare Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Friday, April 3rd will be given a dividend of $0.035 per share. This represents a $0.14 annualized dividend and a dividend yield of 0.2%. The ex-dividend date is Thursday, April 2nd. GE HealthCare Technologies's dividend payout ratio is currently 3.07%.

Wall Street Analysts Forecast Growth

GEHC has been the subject of several recent research reports. Stifel Nicolaus boosted their price target on GE HealthCare Technologies from $95.00 to $98.00 and gave the company a "buy" rating in a research note on Wednesday, February 4th. Evercore upped their target price on GE HealthCare Technologies from $95.00 to $98.00 and gave the company an "outperform" rating in a research report on Thursday, February 5th. Mizuho cut their target price on GE HealthCare Technologies from $95.00 to $90.00 and set an "outperform" rating for the company in a research report on Monday. The Goldman Sachs Group cut their target price on GE HealthCare Technologies from $97.00 to $81.00 and set a "buy" rating for the company in a research report on Thursday, April 9th. Finally, Weiss Ratings reiterated a "hold (c+)" rating on shares of GE HealthCare Technologies in a research report on Monday, December 29th. Eight analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $90.69.

GE HealthCare Technologies Profile

GE HealthCare Technologies NASDAQ: GEHC is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.